Patents by Inventor Daniel S. Kohane

Daniel S. Kohane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190365652
    Abstract: Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one or more ketal, monothioketal, and/or thioketal bonds and a precursor of a pharmaceutically active agent. The precursor of the pharmaceutically active agent may be located in the backbone or may be a pendant group. The polymer may degrade in certain environments (e.g., aqueous environments, acidic environments, in vivo, etc.) to produce the pharmaceutically active agent and other biocompatible degradation f) products, such as certain ketones, alcohols, and/or thiols. Regardless of the location of the precursor of the pharmaceutically active agent in the repeat unit(s), the polymer may have a prolonged degradation time and/or release of the pharmaceutically active agent in certain environments.
    Type: Application
    Filed: April 28, 2017
    Publication date: December 5, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Shutao Guo
  • Publication number: 20190336635
    Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 7, 2019
    Inventors: Jung-Jae Lee, Kyung Jae Jeong, Daniel S. Kohane
  • Publication number: 20190247377
    Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Inventors: Charles Berde, Daniel S. Kohane
  • Patent number: 10369255
    Abstract: The present invention generally relates to nanoscale wires and tissue engineering. In various embodiments, cell scaffolds for growing cells or tissues can be formed that include nanoscale wires that can be connected to electronic circuits extending externally of the cell scaffold. The nanoscale wires may form an integral part of cells or tissues grown from the cell scaffold, and can even be determined or controlled, e.g., using various electronic circuits. This approach allows for the creation of fundamentally new types of functionalized cells and tissues, due to the high degree of electronic control offered by the nanoscale wires and electronic circuits. Accordingly, such cell scaffolds can be used to grow cells or tissues which can be determined and/or controlled at very high resolutions, due to the presence of the nanoscale wires, and such cell scaffolds will find use in a wide variety of novel applications, including applications in tissue engineering, prosthetics, pacemakers, implants, or the like.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 6, 2019
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, Children's Medical Center Corporation
    Inventors: Charles M. Lieber, Jia Liu, Bozhi Tian, Tal Dvir, Robert S. Langer, Daniel S. Kohane
  • Patent number: 10350320
    Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: July 16, 2019
    Assignees: Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Jung-Jae Lee, Kyung Jae Jeong, Daniel S. Kohane
  • Patent number: 10314833
    Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 11, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Charles Berde, Daniel S. Kohane
  • Publication number: 20190125669
    Abstract: The present invention generally relates to compositions, such as gels comprising steroids. In certain aspects, the steroids are modified such that they can form gels, e.g., when complexed to metal ions. In some cases, the steroids form fibers, such as nanofibers, within the gel. For instance, in one set of embodiments, a steroid may be relatively hydrophobic, and/or modified to include a phosphate moiety that is able to complex to metal ions to form the gel. In some cases, such gels may be administered to a subject, e.g., through injection. Other aspects of the invention are generally directed to methods of making or using such gels, kits comprising such gels, or the like.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 2, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Qian Liu
  • Publication number: 20190070115
    Abstract: Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions including an effective amount of one or more sodium channel blockers including site 1 sodium channel blockers, optionally one or more alpha-2-adrenergic agonists, which are optionally encapsulated in liposomes, particles or microbubbles, and one or more triggerable elements are provided. The triggerable elements allow delivery of the encapsulated anesthetic drugs when an appropriate triggering stimuli are applied. Exemplary triggering agents or stimuli include near-infrared irradiation, UV- and visible light, ultrasound and magnetic field. In one embodiment, ultrasound is used to trigger a burst of microbubbles to enhance penetration of local anesthetic.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 7, 2019
    Inventors: Alina Y. Rwei, Changyou Zhan, Kathleen J. Cullion, Daniel S. Kohane
  • Publication number: 20180311353
    Abstract: The present invention generally relates to various photoreactions, including reactions generally based on triplet-triplet annihilation upconversion. One aspect of the present invention is directed to systems and methods for absorbing energy (e.g., from a photon) in a photo sensitizer, transferring that energy by triplet-triplet energy transfer to an annihilator to produce a higher energy state via upconversion, then transferring that energy to cleave a cleavable or other active moiety, for instance, in order to cause the release of a releasable moiety. The energy may be transferred to the moiety via Forster resonance energy transfer. In some cases, these may be contained within a suitable carrier material, for example, a particle or a micelle. Such systems and methods may be used in a variety of applications, including various biological or physical applications.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 1, 2018
    Applicant: Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Weiping Wang, Qian Liu
  • Publication number: 20180228903
    Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 16, 2018
    Applicants: Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Daniel S. Kohane, Rong Yang, Lily Yun Lin
  • Patent number: 10010709
    Abstract: Injectable or implantable drug delivery systems providing on-demand ultrasound-triggered drug release and methods for controlling the release of drug in a patient are provided herein. The on-demand drug delivery systems contain a drug depot and a drug encapsulated in an encapsulating material, where the encapsulating material is different from the depot. In the preferred embodiment, the depot also contains microbubbles that encapsulate one or more gases. The microbubbles enhance the drug release when ultrasound is applied compared to the same system in the absence of microbubbles. In a preferred embodiment, the drug delivery system, contains an encapsulating material, preferably liposomes, a drug to be delivered, microbubbles, and at least two hydrogel-forming precursor components. Following injection or implantation, the patient can control the time, location and dosage released by administering ultrasound.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: July 3, 2018
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Daniel S. Kohane, Hila Epstein-Barash, Mark A. Borden
  • Publication number: 20170368176
    Abstract: Compositions and methods for prolonging the local anesthetic effect of site 1 sodium channel blockers and local anesthetics with minimal or reduced toxicity have been developed for ophthalmic use. It has been established that agents such as dexmedetomidine having alpha-2-adrenergic agonist and Hyperpolarization-activated cyclic nucleotide-gated channel antagonist activity can dramatically prolong the duration of nerve blockade when administered to the surface of, a compartment of or tissue adjacent to, the eye. A preferred active agent for prolonging the local anesthetic effect of site 1 sodium channel blockers or local anesthetics is Dexmedetomidine.
    Type: Application
    Filed: December 14, 2015
    Publication date: December 28, 2017
    Inventors: Daniel S. Kohane, James B. McAlvin, Changyou Zhan
  • Publication number: 20170333338
    Abstract: A composition that achieves sustained oral drug release is provided. The composition includes liposomes, micelles, or polymeric particles, for example, having a hydrophobic core and an amphipathic corona, wherein the core contains a therapeutic, diagnostic, nutraceutical, cosmeceutical or prophylactic agent to be released, and the corona has targeting ligands immobilized to it. In a preferred embodiment the targeting ligands are bisphosphonate molecules, which enable binding to hydroxyapatite present on teeth. The incorporation of short polyethylene glycol (PEG) chains prevents chain entanglement and ionic interactions, minimizes mucus adhesion, increases particle diffusion rates in mucus, and increases the overall stability of particles in saliva. In a preferred embodiment the agent incorporated is a dental bleaching agent and the ligands selectively bind hydroxyapatite.
    Type: Application
    Filed: October 20, 2015
    Publication date: November 23, 2017
    Inventors: Daniel S. Kohane, Ryan Wylie
  • Publication number: 20170252365
    Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
    Type: Application
    Filed: July 26, 2016
    Publication date: September 7, 2017
    Inventors: Ifat RUBIN-BEJERANO, Gerald R. FINK, Claudia ABEIJON, Daniel S. KOHANE, Jason E. FULLER, Robert S. LANGER
  • Publication number: 20170072109
    Abstract: The present invention generally relates to nanoscale wires and tissue engineering. In various embodiments, cell scaffolds for growing cells or tissues can be formed that include nanoscale wires that can be connected to electronic circuits extending externally of the cell scaffold. The nanoscale wires may form an integral part of cells or tissues grown from the cell scaffold, and can even be determined or controlled, e.g., using various electronic circuits. This approach allows for the creation of fundamentally new types of functionalized cells and tissues, due to the high degree of electronic control offered by the nanoscale wires and electronic circuits. Accordingly, such cell scaffolds can be used to grow cells or tissues which can be determined and/or controlled at very high resolutions, due to the presence of the nanoscale wires, and such cell scaffolds will find use in a wide variety of novel applications, including applications in tissue engineering, prosthetics, pacemakers, implants, or the like.
    Type: Application
    Filed: July 21, 2016
    Publication date: March 16, 2017
    Inventors: Charles M. Lieber, Jia Liu, Bozhi Tian, Tal Dvir, Robert S. Langer, Daniel S. Kohane
  • Publication number: 20160331774
    Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 17, 2016
    Inventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E. Fuller, Robert S. Langer
  • Patent number: 9457047
    Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: October 4, 2016
    Assignees: Whitehead Institute, Massachusetts Institute of Technology, Trustees of Boston University, The General Hospital Corporation
    Inventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E Fuller, Robert S. Langer
  • Patent number: 9457128
    Abstract: The present invention generally relates to nanoscale wires and tissue engineering. In various embodiments, cell scaffolds for growing cells or tissues can be formed that include nanoscale wires that can be connected to electronic circuits extending externally of the cell scaffold. The nanoscale wires may form an integral part of cells or tissues grown from the cell scaffold, and can even be determined or controlled, e.g., using various electronic circuits. This approach allows for the creation of fundamentally new types of functionalized cells and tissues, due to the high degree of electronic control offered by the nanoscale wires and electronic circuits. Accordingly, such cell scaffolds can be used to grow cells or tissues which can be determined and/or controlled at very high resolutions, due to the presence of the nanoscale wires, and such cell scaffolds will find use in a wide variety of novel applications, including applications in tissue engineering, prosthetics, pacemakers, implants, or the like.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: October 4, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: Charles M. Lieber, Jia Liu, Bozhi Tian, Tal Dvir, Robert S. Langer, Daniel S. Kohane
  • Patent number: 9408846
    Abstract: A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain, such as hyperalgesia and/or allodynia, for at least one week, and preferably longer at the site, and preferably the region (e.g. entire limb), where the nerve block was applied. The site 1 sodium channel blocker is preferably saxitoxin (STX), preferably in combination with a corticosteroid, preferably dexamethasone. In a preferred embodiment, liposomes are included in the formulation as a controlled release system, producing prolonged duration of block without systemic toxicity. As demonstrated by the examples, encapsulating STX in a controlled release system, such as liposomes, preferably also including a corticosteroid, and administering in suitable dosing regimen to achieve a prolonged nerve block without systemic toxicity, delays the onset of hyperalgesia.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: August 9, 2016
    Assignee: The Children's Medical Center Corporation
    Inventors: Sahadev Aramanethalgur Shankarappa, Daniel S. Kohane
  • Publication number: 20160206561
    Abstract: A complex coacervate delivery system is provided which encapsulates lipophilic nutrients such as, for example, fish oils high in omega-3 fatty acids. The complex coacervate delivery system protects the lipophilic nutrient from degradation, e.g., oxidation and hydrolysis, and also reduces or eliminates the unpleasant taste and odor of the lipophilic nutrient. The complex coacervate delivery system upon ingestion is operative to substantially release the lipophilic nutrient in the lower gastrointestinal tract in a pH-controlled manner. The complex coacervate delivery system may be included in a food or beverage product having a pH value within the range of about 1.5 to about 5.0.
    Type: Application
    Filed: November 17, 2015
    Publication date: July 21, 2016
    Inventors: Daniel S. KOHANE, Yoon YEO, Peter GIVEN, Robert S. LANGER